ACT-GLOBAL: An Adaptive Platform Trial for Acute Ischemic Stroke Treatments
/Summary
The ACT-GLOBAL study, led by stroke clinicians and researchers from the University of Calgary and the George Institute for Global Public Health, is a pioneering Stroke-focussed Adaptive Platform Trial designed to explore multiple clinical questions simultaneously. This innovative trial design aims to enhance the efficiency of data collection, accelerating the discovery of optimal treatments for acute stroke.
Currently, ACT-GLOBAL is addressing several pressing questions in stroke care, such as:
What is the optimal dose of intravenous thrombolysis?
Should thrombolysis be administered before or after endovascular thrombectomy in eligible patients?
Can neuroprotective therapies effectively prevent brain cell death when combined with thrombolysis?
What is the ideal blood pressure target following thrombectomy?
By systematically evaluating these critical interventions, ACT-GLOBAL seeks to identify the best evidence-based approaches to improve outcomes for stroke patients worldwide.
Primary Video: https://youtu.be/7wiQWxSCXUg
Participation Invitation
We are actively seeking additional trial sites to join this initiative. Your participation can help shape the future of stroke care, contributing to improved outcomes for patients globally.
Contact Information
For more information or to express interest in joining the ACT-GLOBAL trial, please contact:
Email: info@actglobaltrial.org, docbijoymenon@gmail.com, ademchuk@ucalgary.ca
Website: Visit the ACT-GLOBAL trial site
We look forward to collaborating with you !